Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer.
Vito LorussoAgnese LatorreFrancesco GiottaPublished in: Journal of oncology (2020)
Despite the recent advances in the biological understanding of breast cancer (BC), chemotherapy still represents a key component in the armamentarium for this disease. Different agents are available as mono-chemotherapy options in patients with locally advanced or metastatic BC (MBC) who progress after a first- and second-line treatment with anthracyclines and taxanes. However, no clear indication exists on what the best option is in some populations, such as heavily pretreated, elderly patients, triple-negative BC (TNBC), and those who do not respond to the first-line therapy. In this article, we summarize available literature evidence on different chemotherapy agents used beyond the first-line, in locally advanced or MBC patients, including rechallenge with anthracyclines and taxanes, antimetabolite and antimicrotubule agents, such as vinorelbine, capecitabine, eribulin, ixabepilone, and the newest developed agents, such as vinflunine, irinotecan, and etirinotecan.
Keyphrases
- locally advanced
- rectal cancer
- squamous cell carcinoma
- phase ii study
- metastatic breast cancer
- neoadjuvant chemotherapy
- radiation therapy
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- clinical trial
- peritoneal dialysis
- stem cells
- open label
- young adults
- mesenchymal stem cells
- patient reported outcomes
- cell therapy
- bone marrow